I can't say we've seen any hype this year, at least not from the company. In fact we've seen nothing yet, which I somewhat expected when I sold a few of my shares to get a tax loss, that I previously mentioned when I did it. On Monday I should be free to buy back those shares and intend to.

Meanwhile feeling that cannabis could get hot did invest the money in a few other companies, most of which have done nothing, but just this week bought RSII which has taken off. I posted some information about it, but I'm not certain if I did it here, like OWCP they have a pill but it sounds like it gives more of a jolt than the longer effect of our sublingual product, but they appear close to approval for use in Ohio. I'm hoping that they're like OWCP awhile ago when it was sub-penny, wish I had gotten involved then.

I do believe the company will have something to say before or at the time of the Wall St. Conf., but while they may know the safety trial should be concluded by then, all we know is they've said it would be complete this quarter, they really didn't say it, it was shown in the timeline in their most recent presentation. I would suspect that we'll have an update of that presentation by the time of the conference and hopefully we'll get more news than that. Of course the Annual Report is due no later than the end of March and that certainly should tell us a lot more about what's anticipated during the remainder of the year. I won't call this hype, but I can't say how others will label it.

Gary